Haloperidol Cf

Haloperidol Cf is a generic oral medication that contains the active ingredient haloperidol. It is classified as a typical antipsychotic of the butyrophenone class and is supplied in the European market by an unnamed manufacturer. The product is intended for prescription use and is administered by mouth to manage certain psychiatric conditions.

Haloperidol Cf is prescribed for several psychiatric disorders where dopamine blockade is beneficial.

- Management of schizophrenia, including acute exacerbations. - Treatment of acute psychotic episodes unrelated to schizophrenia. - Control of manic episodes in bipolar disorder. - Reduction of motor and vocal tics associated with Tourette syndrome. - Adjunct therapy for severe agitation or aggression when other options are insufficient.

Haloperidol Cf may cause a range of side effects that vary in frequency and severity.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor or rigidity. - Dry mouth and blurred vision. - Constipation or gastrointestinal discomfort. - Weight gain or increased appetite. - Orthostatic hypotension leading to dizziness.

Serious: - Neuroleptic malignant syndrome, a potentially life‑threatening reaction. - Tardive dyskinesia, characterized by involuntary facial movements. - Severe cardiac arrhythmias, including QT prolongation. - Hyperprolactinemia causing menstrual disturbances or galactorrhea. - Significant depression or suicidal thoughts. - Allergic reactions such as rash, swelling, or anaphylaxis.

Before initiating Haloperidol Cf, clinicians should assess patient history and monitor for specific risks.

- Evaluate cardiovascular status, especially for QT interval prolongation. - Screen for a personal or family history of movement disorders. - Use caution in patients with hepatic or renal impairment. - Monitor blood glucose and lipid levels in patients at risk for metabolic changes. - Assess for signs of depression or suicidal ideation during treatment. - Discuss potential pregnancy and lactation considerations with women of childbearing age. - Regularly review the need for continued therapy to avoid long‑term adverse effects.

Haloperidol Cf can interact with several drug classes, influencing its safety and effectiveness.

Avoid: - Other dopamine antagonists or antipsychotics that may increase extrapyramidal risk. - Medications that prolong the QT interval, such as certain antiarrhythmics and macrolide antibiotics. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol plasma levels.

Use with caution: - CNS depressants, including benzodiazepines and alcohol, which can enhance sedation. - Anticholinergic agents that may mask extrapyramidal symptoms. - CYP2D6 substrates (e.g., metoprolol) as haloperidol may affect their metabolism.